Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered question first ministerially corrected answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

100642

registered interest
date	23/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Transatlantic Trade and Investment Partnership
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether they have undertaken an impact assessment of the potential impacts on the National Health Service of the Transatlantic Trade and Investment Partnership which is being negotiated between the European Union and the United States.
tabling member printed	Baroness Manzoor
uin	HL2373
answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The Transatlantic Trade and Investment Partnership (TTIP) will not affect the way the United Kingdom Government runs the National Health Service. It has been made clear by negotiators from both the United States and the European Union that it is up to the UK alone to decide how the NHS is run and any assertion that TTIP will undermine the Government’s control of the NHS is a red herring.</p><p> </p><p> </p><p> </p><p>The TTIP could offer great benefits to British business and for British jobs. Greater consistency in existing and new regulatory requirements would make it easier for companies - especially small and medium enterprises - to access markets and, for patients, potentially help to increase access to new medicines and medical devices.</p><p> </p> answering member printed Earl Howe grouped question UIN HL2374 HL2375 question first answered 29/10/2014 12:27:46 answering member 2000 label Biography information for Earl Howe
tabling member	4289 label Biography information for Baroness Manzoor

100643

registered interest
date	23/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Transatlantic Trade and Investment Partnership
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what are the implications for the National Health Service and the staff who work in the National Health Service if the Transatlantic Trade and Investment Partnership is agreed.
tabling member printed	Baroness Manzoor
uin	HL2374
answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The Transatlantic Trade and Investment Partnership (TTIP) will not affect the way the United Kingdom Government runs the National Health Service. It has been made clear by negotiators from both the United States and the European Union that it is up to the UK alone to decide how the NHS is run and any assertion that TTIP will undermine the Government’s control of the NHS is a red herring.</p><p> </p><p> </p><p> </p><p>The TTIP could offer great benefits to British business and for British jobs. Greater consistency in existing and new regulatory requirements would make it easier for companies - especially small and medium enterprises - to access markets and, for patients, potentially help to increase access to new medicines and medical devices.</p><p> </p> answering member printed Earl Howe grouped question UIN HL2373 HL2375 question first answered 29/10/2014 12:27:47 answering member 2000 label Biography information for Earl Howe
tabling member	4289 label Biography information for Baroness Manzoor

100644

registered interest
date	23/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Transatlantic Trade and Investment Partnership
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what are the implications for hospitals and foundation trusts if the Transatlantic Trade and Investment Partnership is agreed.
tabling member printed	Baroness Manzoor
uin	HL2375
answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The Transatlantic Trade and Investment Partnership (TTIP) will not affect the way the United Kingdom Government runs the National Health Service. It has been made clear by negotiators from both the United States and the European Union that it is up to the UK alone to decide how the NHS is run and any assertion that TTIP will undermine the Government’s control of the NHS is a red herring.</p><p> </p><p> </p><p> </p><p>The TTIP could offer great benefits to British business and for British jobs. Greater consistency in existing and new regulatory requirements would make it easier for companies - especially small and medium enterprises - to access markets and, for patients, potentially help to increase access to new medicines and medical devices.</p><p> </p> answering member printed Earl Howe grouped question UIN HL2373 HL2374 question first answered 29/10/2014 12:27:46 answering member 2000 label Biography information for Earl Howe
tabling member	4289 label Biography information for Baroness Manzoor

100715

registered interest
date	23/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Mental Health Services: Children and Young People
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of waiting times for young people attempting to access child and adolescent mental health services; and if he will publish average national waiting times in each of the years 2011, 2012 and 2013.
tabling member constituency	Barnsley Central
tabling member printed	Dan Jarvis
uin	211725
answer	answer is ministerial correction date of answer 28/10/2014 answer text <p>Average national waiting times in each of the years 2011, 2012 and 2013 will not be published as information on waiting times for Child and Adolescent Mental Health Services is not collected centrally. There is anecdotal evidence of increasing waiting times in some areas. We do not know whether or not this is due to an increase in referrals or in the prevalence of mental health conditions but will be seeking further information by commissioning a survey into the prevalence of mental illness in children and young people.</p><p> </p><p><br> <br></p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 28/10/2014 14:48:00 answering member 1439 label Biography information for Norman Lamb
tabling member	4243 label Biography information for Dan Jarvis

100717

registered interest
date	23/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Assistive Technology: Annual Reports
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will publish the Impact Assessment for his Department's decision to bring the production of the annual report on Research and Development Work Relating to Assistive Technology in house from 2015.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	211710
answer	answer is ministerial correction date of answer 30/10/2014 answer text <p>Section 22 of the Chronically Sick and Disabled Persons Act 1970 sets out the following requirement:</p><p> </p><p> </p><p> </p><p>“The Secretary of State shall as respects each year lay before Parliament a report on the progress made during that year in research and development work carried out by or on behalf of any Minister of the Crown in relation to equipment that might increase the range of activities and independence or well-being of disabled persons, and in particular such equipment that might improve the indoor and outdoor mobility of such persons.”</p><p> </p><p> </p><p> </p><p>In recent years the report has been produced by the Foundation for Assistive Technology and this contract expired in June 2014 following production of the report for 2013-14. Future reports will be produced by the Department and it is expected that the report for 2014-15 will be laid before Parliament and published in July 2015.</p><p> </p><p>There has been no specific impact or risk assessment. The Government will continue to meet the requirement set out in section 22.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 211707 211708 211709 question first answered 30/10/2014 16:13:24 answering member 4020 label Biography information for George Freeman
tabling member	1506 label Biography information for Andrew Gwynne

100718

registered interest
date	23/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Assistive Technology: Annual Reports
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he plans to publish the next annual report on Research and Development Work Relating to Assistive Technology.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	211707
answer	answer is ministerial correction date of answer 30/10/2014 answer text <p>Section 22 of the Chronically Sick and Disabled Persons Act 1970 sets out the following requirement:</p><p> </p><p> </p><p> </p><p>“The Secretary of State shall as respects each year lay before Parliament a report on the progress made during that year in research and development work carried out by or on behalf of any Minister of the Crown in relation to equipment that might increase the range of activities and independence or well-being of disabled persons, and in particular such equipment that might improve the indoor and outdoor mobility of such persons.”</p><p> </p><p> </p><p> </p><p>In recent years the report has been produced by the Foundation for Assistive Technology and this contract expired in June 2014 following production of the report for 2013-14. Future reports will be produced by the Department and it is expected that the report for 2014-15 will be laid before Parliament and published in July 2015.</p><p> </p><p>There has been no specific impact or risk assessment. The Government will continue to meet the requirement set out in section 22.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 211708 211709 211710 question first answered 30/10/2014 16:13:23 answering member 4020 label Biography information for George Freeman
tabling member	1506 label Biography information for Andrew Gwynne

100719

registered interest
date	23/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Assistive Technology: Annual Reports
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he expects the next annual report on Research and Development Work Relating to Assistive Technology to be laid before parliament.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	211708
answer	answer is ministerial correction date of answer 30/10/2014 answer text <p>Section 22 of the Chronically Sick and Disabled Persons Act 1970 sets out the following requirement:</p><p> </p><p> </p><p> </p><p>“The Secretary of State shall as respects each year lay before Parliament a report on the progress made during that year in research and development work carried out by or on behalf of any Minister of the Crown in relation to equipment that might increase the range of activities and independence or well-being of disabled persons, and in particular such equipment that might improve the indoor and outdoor mobility of such persons.”</p><p> </p><p> </p><p> </p><p>In recent years the report has been produced by the Foundation for Assistive Technology and this contract expired in June 2014 following production of the report for 2013-14. Future reports will be produced by the Department and it is expected that the report for 2014-15 will be laid before Parliament and published in July 2015.</p><p> </p><p>There has been no specific impact or risk assessment. The Government will continue to meet the requirement set out in section 22.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 211707 211709 211710 question first answered 30/10/2014 16:13:24 answering member 4020 label Biography information for George Freeman
tabling member	1506 label Biography information for Andrew Gwynne

100720

registered interest
date	23/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Osteoporosis: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how much has been spent on prescriptions for the treatment of osteoporosis in each of the last five years.
tabling member constituency	Leicester West
tabling member printed	Liz Kendall
uin	211731
answer	answer is ministerial correction date of answer 30/10/2014 answer text <p>Information on National Health Service expenditure on drugs for the treatment of osteoporosis in primary and secondary care is in the table.</p><p> </p><p> </p><p> </p><p>Drugs for the treatment of osteoporosis have been defined as those included in the following British National Formulary sections:</p><p> </p><p>6.6 Drugs affecting bone metabolism</p><p> </p><p>9.5.1.1 Calcium supplements</p><p> </p><p>9.6 Vitamins (colecalciferol and ergocalciferol only)</p><p> </p><p><strong> </strong></p><p> </p><table><tbody><tr><td colspan="11"><p>Cost of drugs for the treatment of osteoporosis, England<sup>1</sup></p></td></tr><tr><td><p>Drug Name<sup>2</sup></p></td><td colspan="5"><p>Primary Care</p><p>(£ million)</p></td><td colspan="5"><p>Secondary Care</p><p>(£ million)</p></td></tr><tr><td><p>Year</p></td><td><p>2009</p></td><td><p>2010</p></td><td><p>2011</p></td><td><p>2012</p></td><td><p>2013</p></td><td><p>2009</p></td><td><p>2010</p></td><td><p>2011</p></td><td><p>2012</p></td><td><p>2013</p></td></tr><tr><td><p>Alendronic Acid</p></td><td><p>14.0</p></td><td><p>12.4</p></td><td><p>10.8</p></td><td><p>9.7</p></td><td><p>8.9</p></td><td><p>0.8</p></td><td><p>0.6</p></td><td><p>0.5</p></td><td><p>0.5</p></td><td><p>0.4</p></td></tr><tr><td><p>Alendronic Acid and Colecalciferol</p></td><td><p>1.4</p></td><td><p>1.2</p></td><td><p>0.9</p></td><td><p>0.7</p></td><td><p>0.6</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td></tr><tr><td><p>Calcitonin (Salmon)</p></td><td><p>0.3</p></td><td><p>0.3</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.1</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td></tr><tr><td><p>Calcium</p></td><td><p>4.2</p></td><td><p>4.7</p></td><td><p>4.5</p></td><td><p>3.7</p></td><td><p>3.3</p></td><td><p>0.9</p></td><td><p>0.9</p></td><td><p>0.9</p></td><td><p>0.9</p></td><td><p>0.9</p></td></tr><tr><td><p>Calcium and Colecalciferol</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>2.2</p></td><td><p>2.2</p></td><td><p>2.1</p></td><td><p>2.2</p></td><td><p>2.3</p></td></tr><tr><td><p>Clodronic Acid</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>2.9</p></td><td><p>2.4</p></td><td><p>1.6</p></td><td><p>1.2</p></td><td><p>0.9</p></td></tr><tr><td><p>Colecalciferol</p></td><td><p>42.4</p></td><td><p>48.3</p></td><td><p>58.5</p></td><td><p>67.6</p></td><td><p>75.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.4</p></td><td><p>1.2</p></td></tr><tr><td><p>Denosumab</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.2</p></td><td><p>0.8</p></td><td><p>1.9</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.9</p></td><td><p>2.3</p></td><td><p>9.9</p></td></tr><tr><td><p>Disodium Etidronate</p></td><td><p>1.3</p></td><td><p>1.0</p></td><td><p>0.8</p></td><td><p>0.6</p></td><td><p>0.3</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td></tr><tr><td><p>Ergocalciferol</p></td><td><p>4.3</p></td><td><p>7.8</p></td><td><p>8.0</p></td><td><p>7.0</p></td><td><p>6.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.2</p></td><td><p>0.3</p></td></tr><tr><td><p>Ibandronic Acid</p></td><td><p>12.1</p></td><td><p>12.1</p></td><td><p>11.4</p></td><td><p>10.6</p></td><td><p>4.7</p></td><td><p>2.1</p></td><td><p>2.0</p></td><td><p>1.8</p></td><td><p>1.5</p></td><td><p>0.9</p></td></tr><tr><td><p>Pamidronic Acid</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>9.6</p></td><td><p>9.1</p></td><td><p>9.4</p></td><td><p>9.4</p></td><td><p>8.7</p></td></tr><tr><td><p>Risedronate Sodium and Risedronate Acid</p></td><td><p>27.9</p></td><td><p>22.9</p></td><td><p>11.6</p></td><td><p>2.4</p></td><td><p>2.0</p></td><td><p>0.8</p></td><td><p>0.6</p></td><td><p>0.3</p></td><td><p>0.1</p></td><td><p>0.1</p></td></tr><tr><td><p>Sodium Clodronate</p></td><td><p>7.8</p></td><td><p>7.2</p></td><td><p>6.3</p></td><td><p>5.5</p></td><td><p>4.3</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td></tr><tr><td><p>Strontium Ranelate</p></td><td><p>7.0</p></td><td><p>7.8</p></td><td><p>9.0</p></td><td><p>9.2</p></td><td><p>7.3</p></td><td><p>0.6</p></td><td><p>0.6</p></td><td><p>0.6</p></td><td><p>0.5</p></td><td><p>0.2</p></td></tr><tr><td><p>Teriparatide</p></td><td><p>0.3</p></td><td><p>0.4</p></td><td><p>0.4</p></td><td><p>0.5</p></td><td><p>0.6</p></td><td><p>2.7</p></td><td><p>2.8</p></td><td><p>2.7</p></td><td><p>3.1</p></td><td><p>3.2</p></td></tr><tr><td><p>Zoledronic Acid</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>16.7</p></td><td><p>18.0</p></td><td><p>20.9</p></td><td><p>23.7</p></td><td><p>25.7</p></td></tr><tr><td><p>Other Calcium Supplement Preps</p></td><td><p>0.5</p></td><td><p>0.6</p></td><td><p>0.6</p></td><td><p>0.5</p></td><td><p>0.5</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td></tr><tr><td><p>Other drugs<sup>3</sup></p></td><td><p>0.2</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.2</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.0</p></td></tr><tr><td><p>TOTAL</p></td><td><p>123.8</p></td><td><p>126.8</p></td><td><p>123.4</p></td><td><p>119.1</p></td><td><p>115.4</p></td><td><p>39.6</p></td><td><p>39.6</p></td><td><p>42.3</p></td><td><p>46.2</p></td><td><p>55.0</p></td></tr></tbody></table><p> </p><p><sup>1 </sup>Cost of drugs at NHS list price. It does not take account of discounts, dispensing costs, fees or prescription charges income. Totals may not add up due to rounding.</p><p> </p><p><sup>2</sup> The patent for some of these drugs may have expired during this period.</p><p> </p><p><sup>3</sup> “Other drugs” includes Calcium and Colecalciferol and Ergocalciferol, Calcium and Etidronic Acid, Calcium and Risedronic and Colecalciferol, Disodium Pamidronate, Ergocalciferol and Calcium, Etidronic Acid, Hydroxyapatite, Parathyroid Hormone, Salcatonin, Tiludronic Acid, other Bisphosphonate and other Preparations.</p><p> </p><p> </p><p> </p><p><em>Source: </em></p><p> </p><p>Prescription Cost Analysis (PCA) provided by the Health and Social Care Information Centre (primary care)</p><p> </p><p>Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care)</p><p> </p><p> </p><p> </p><p>Since some drugs are prescribed to treat more than one condition and as the condition for which a drug is prescribed is not collected, it is not possible to separate the different conditions for which a drug may have been prescribed. The information provided may therefore include costs from the prescribing of these drugs for conditions other than for osteoporosis.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 30/10/2014 16:09:20 answering member 4020 label Biography information for George Freeman
tabling member	4026 label Biography information for Liz Kendall

100721

registered interest
date	23/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Osteoporosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how much from the publich purse has been spent on research into osteoporosis in each of the last five years.
tabling member constituency	Leicester West
tabling member printed	Liz Kendall
uin	211732
answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2014 17:12:28 question first ministerially corrected 13/11/2014 10:22:56 answering member 4020 label Biography information for George Freeman previous answer version 25123 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
tabling member	4026 label Biography information for Liz Kendall

100722

registered interest
date	23/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Neurology: Nurses
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many full-time equivalent specialist nurses for a neurological condition were employed in each region of England in each of the last five years.
tabling member constituency	Leicester West
tabling member printed	Liz Kendall
uin	211733
answer	answer is ministerial correction date of answer 30/10/2014 answer text <p>The National Health Service annual workforce census provides information on the number of nursing, midwifery and health visiting staff employed in the NHS in England but does not separately identify specialist nurses employed in neurological conditions.</p><p> </p><p> </p><p> </p><p>It is for local NHS organisations with their knowledge of the healthcare needs of their local population to invest in training for specialist skills and to deploy specialist nurses. Specialist nurses provide invaluable support for patients and their families. They are able to provide specialist treatment and advice and act as a gateway to other members of the multidisciplinary team, which can both save the NHS money and, more importantly, improve care and outcomes for patients.</p><p> </p><p> </p><p> </p><p>Health Education England (HEE) supports employers with Continuous Personal and Professional Development. HEE's planning process has created the opportunity for employers, through their membership of local education training boards, to prioritise investment between training the future supply of healthcare professional and the development of existing staff, but it is currently for these local partnerships to identify their relative priorities for investment.</p><p> </p><p> </p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 30/10/2014 16:25:48 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	4026 label Biography information for Liz Kendall